Data from Pharmawand - Curated by EPG Health - Date added 05 January 2019

The National Institute for Health and Care Excellence has recommended that Fasenra (benralizumab), from AstraZeneca, be available to people with severe eosinophilic asthma on the NHS in England and Wales. The therapy is given with a dosage as an injection every four weeks for the first three doses, and every eight weeks thereafter. This makes it potentially more convenient than Nucala (mepolizumab), which is also injected, but every four weeks.

In an earlier appraisal consultation document, NICE had concluded that the drug was not cost-effective, but an improved patient access scheme from AZ helped overturn this position.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Load more

Related Content